EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Editorial Comment: Managing Cardiac Implantable Electronic Device Infections: Lessons from a Prospective Registry

Pir Sheeraz Ali

Pakistan Heart Journal · 2026-10-31 · 59 (5) · 1688-1690

DOI: 10.47144/phj.v59i5.4040 ↗
AbstractBibliografische Angaben

Abstract

Cardiac implantable electronic devices (CIEDs), including permanent pacemakers, implantable cardioverter-defibrillators (ICDs), and cardiac resynchronization therapy (CRT) devices, are integral to the treatment of cardiac arrhythmias and heart failure. However, CIED-related infections remain a serious complication, associated with substantial morbidity, mortality, and healthcare expenditure. As device implantation, generator replacement, and use of increasingly complex systems become more common, effective prevention and management of these infections are increasingly important. International consensus recommendations identify complete removal of infected hardware, including the generator and associated leads, as the cornerstone of treatment for established CIED infection [1]. Antimicrobial therapy is essential but generally cannot eradicate infection when infected hardware remains in place. Observational evidence has linked delayed extraction with higher mortality, particularly in patients with systemic infection [2,3]. Although these associations do not establish causality, they support prioritizing timely source control rather than extending antimicrobial treatment while awaiting extraction. Against this background, a prospective registry from the National Heart Institute in Cairo offers useful insights into CIED infection management and the possible role of care outside the hospital before extraction [4]. The registry enrolled 100 patients between December 2021 and April 2023 and applied standardized diagnostic and management protocols. All patients underwent complete system extraction, and none were lost to follow-up during the six-month observation period. Uncomplicated pocket infection was the most common presentation, and coagulase-negative staphylococci predominated among identified organisms. Approximately 60% of cultures were negative; prior antibiotic exposure is one possible explanation, although this cannot be established from the reported observation alone. Within six months, the registry reported no deaths, one recurrent infection, and device reimplantation in 82% of patients. These outcomes are encouraging, but the relatively small sample and limited follow-up constrain conclusions about uncommon or later complications. Notably, the median interval from diagnosis to extraction was approximately two weeks. This interval warrants scrutiny, although the relative contributions of referral processes, clinical decisions, and extraction-service capacity cannot be determined without additional data. Of particular interest, 18 patients, mostly presenting with uncomplicated pocket infections, received antibiotics outside the hospital while awaiting extraction rather than remaining hospitalized for intravenous treatment. No apparent increase in reinfection or readmission was reported in this subgroup compared with hospitalized patients. This finding suggests that selected, clinically stable patients might be managed without prolonged pre-extraction admission, provided that close follow-up and prompt access to definitive treatment are assured. However, the comparison should not be interpreted as demonstrating the safety or equivalence of outpatient and inpatient strategies. Treatment allocation was nonrandomized and likely influenced by infection severity, clinical stability, and physician judgment, creating substantial potential for selection bias and confounding by indication. With only 18 patients in the outpatient group and very few adverse events overall, the registry was not adequately positioned to exclude clinically important differences. The findings are therefore hypothesis-generating and require confirmation in larger, appropriately designed studies. These observations have relevance for Pakistan, where specialized lead extraction services are concentrated in tertiary cardiac centers. A local study has reported associations between CIED infection and factors including diabetes, hypertension, left ventricular dysfunction, multiple leads, and previous device procedures [5]. Another study from Pakistan found limited predictive performance of the PADIT risk score in its study population [6]. Together, these findings underscore the importance of evaluating risk assessment and service-delivery strategies in local clinical settings, rather than assuming that results from other populations are directly transferable. Crucially, avoiding unnecessary hospitalization must not become a justification for delaying definitive treatment. Ambulatory antibiotic therapy may be considered only for carefully selected patients with localized infection who are clinically stable and can reliably access monitoring and extraction services. Patients with systemic infection, hemodynamic instability, or suspected endocarditis require urgent inpatient evaluation, appropriate antimicrobial therapy, and expedited device removal. Any outpatient pathway should include clear eligibility criteria, safety-net instructions, and a defined extraction timeline. The Cairo registry draws attention to potentially modifiable aspects of care: referral pathways, timely access to experienced extraction teams, and appropriate allocation of inpatient resources. Multicenter prospective research across Pakistan, South Asia, and the Middle East should evaluate explicit patient-selection criteria, time to extraction, adverse events, costs, and patient-reported outcomes. Such work could inform regionally appropriate pathways without compromising established principles of infection management. The Cairo experience raises a clinically relevant question about whether some stable patients with localized CIED infection can safely await extraction outside the hospital. Its observational findings are insufficient to change practice on their own. The central message remains clear: complete and timely removal of infected hardware is essential, and efforts to reduce pre-extraction hospitalization must never come at the expense of prompt definitive care. References Blomström-Lundqvist C, Traykov V, Erba PA, Burri H, Nielsen JC, Bongiorni MG, et al. European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections. Europace. 2020;22(4):515-49. DOI: 10.1093/europace/euz246 Le KY, Sohail MR, Friedman PA, Uslan DZ, Cha SS, Hayes DL, et al. Impact of timing of device removal on mortality in patients with cardiovascular implantable electronic device infections. Heart Rhythm. 2011;8(11):1678-85. DOI: 10.1016/j.hrthm.2011.05.015 Lee JZ, Majmundar M, Kumar A, Thakkar S, Patel HP, Sorajja D, et al. Impact of timing of transvenous lead removal on outcomes in infected cardiac implantable electronic devices. Heart Rhythm. 2022;19(5):768-75. DOI: 10.1016/j.hrthm.2021.12.023 Sadek YA, Khaled SAH, Ismail MF, Abbady AMHME, Katta AA. Optimizing management of cardiac implantable electronic device infections: insights from a prospective registry. Pak Heart J. 2026;59(5):1678-1687. DOI: 10.47144/phj.v59i5.3296 Kubra G, Irfan G, Abbas SG, Aamir KF, Baloch MW, Mueed A. Cardiac implantable electronic device (CIED) infections, associated risk factors and optimization in reducing CIED infections; an experience of tertiary care hospital of Pakistan. Pak Armed Forces Med J. 2024;74(1):49-53. DOI: 10.51253/pafmj.v74i1.8171 Nazir F, Nazir MTB, Khan QH, Javed MU. Assessing the effectiveness of the PADIT score in predicting CIED infections: insights from a tertiary care center. Pak Heart J. 2025;58(1):59-64. DOI: 10.47144/phj.v58i1.2775

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →